Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 19/20 | 0.44 |
| ▸ | JAK2 | O60674 | 18/20 | 0.44 |
| ▸ | JAK3 | P52333 | 18/20 | 0.44 |
| ▸ | TYK2 | P29597 | 11/20 | 0.43 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.38 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3313058 | 1.00 | JAK1 (0.44) | JAK1JAK2JAK3TYK2NUAK1 | |
| SCHEMBL13398091 | 0.90 | JAK2 (0.41) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL13398348 | 0.90 | JAK1 (0.47) | JAK1JAK2JAK3TYK2NUAK1 | |
| SCHEMBL3314606 | 0.90 | JAK1 (0.46) | JAK1JAK2JAK3TYK2NUAK1 | |
| SCHEMBL13398325 | 0.87 | JAK3 (0.43) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL13398350 | 0.86 | JAK2 (0.50) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL13398110 | 0.85 | JAK1 (0.53) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL13398336 | 0.84 | JAK3 (0.58) | JAK1JAK2JAK3TYK2NUAK2 | |
| SCHEMBL13398366 | 0.84 | JAK1 (0.48) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL13398296 | 0.82 | JAK3 (0.43) | JAK1JAK2JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105661-A1 | CONDENSED PYRIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105661-A1 | CONDENSED PYRIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105661-A1 | CONDENSED PYRIDINE COMPOUND | JAK3, IRAK3, JAK1 | JAK1 3/4885JAK2 5/4885JAK3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.